ong Term Immunogenicity of the JE Vaccine IC51
Phase 3
- Conditions
- Prophylactic Vaccine against Japanese EncephalitisNeurological - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)
- Registration Number
- ACTRN12605000681651
- Lead Sponsor
- Intercell AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Healthy subjects. Written informed consent obtained prior to study entry.
Exclusion Criteria
No exclusion criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective is to assess the immunogenicity of the JE vaccine IC51 in subjects[24 months after the first vaccination]
- Secondary Outcome Measures
Name Time Method To investigate the safety 6 months after the first vaccination and the frequency of vaccination-related adverse events during the study period.[]